8-K: Matinas BioPharma Receives NYSE Noncompliance Notice for Failure to Hold Annual Meeting

Matinas BioPharma received a notice from the NYSE American for failing to hold its annual meeting of stockholders, potentially impacting its listing status.

Summary

• Matinas BioPharma Holdings, Inc. received a deficiency letter from the NYSE American on January 6, 2025, because it did not hold an annual meeting of stockholders during the fiscal year ended December 31, 2024.
• This is a violation of Section 704 of the NYSE American Company Guide.
• The notice does not immediately affect the listing of the company's common stock, which will continue to trade on the NYSE American.
• However, the company's stock will be assigned a '.BC' indicator to signify non-compliance.
• Matinas BioPharma intends to hold its annual meeting by December 31, 2025, to regain compliance with the NYSE American Company Guide.
• The company is also evaluating alternatives, including a potential wind-down or dissolution.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the noncompliance notice from the NYSE American and the consideration of a potential wind-down or dissolution of the company.

Positives

• The notice has no immediate impact on the listing of the company's common stock.
• The company intends to hold its annual meeting no later than December 31, 2025 in order to regain compliance under the Company Guide.

Negatives

• Matinas BioPharma failed to hold its annual meeting of stockholders during its fiscal year ended December 31, 2024, violating NYSE American Company Guide requirements.
• The company's stock will be assigned a '.BC' indicator, signaling non-compliance to investors.

Risks

• Failure to hold the annual meeting by December 31, 2025, could lead to further action by the NYSE American.
• The company is evaluating alternatives, including a wind-down or dissolution, indicating potential financial instability.
• The company's product candidates are all in a development stage and are not available for sale or use.

Future Outlook

The company intends to hold its annual meeting no later than December 31, 2025, to regain compliance with NYSE American listing standards, but is also evaluating other alternatives for the Company, including a winddown or dissolution of the Company.

Management Comments

• Jerome Jabbour, Chief Executive Officer, is listed as the contact for investor relations.

Industry Context

Biopharmaceutical companies must adhere to exchange listing requirements, including holding annual meetings, to maintain investor confidence and market access. Failure to comply can raise concerns about corporate governance and financial stability.

Comparison to Industry Standards

• Many companies such as Amgen, Gilead Sciences, and Regeneron Pharmaceuticals hold annual meetings to comply with listing requirements and engage with shareholders.
• Failure to hold an annual meeting is a significant deviation from standard corporate governance practices among publicly listed companies.

Stakeholder Impact

• Shareholders may be concerned about the company's compliance with listing standards and the potential impact on the stock price.
• Employees may be concerned about the potential for a wind-down or dissolution of the company.
• Creditors may be concerned about the company's financial stability.

Next Steps

• Matinas BioPharma intends to hold its annual meeting no later than December 31, 2025.
• The company will need to demonstrate compliance with NYSE American listing standards to remove the '.BC' indicator.

Key Dates